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Abstract
Background: Hyperammonemia induces neuroinflammation and increases GABAergic tone in the cerebellum
which contributes to cognitive and motor impairment in hepatic encephalopathy (HE). The link between
neuroinflammation and GABAergic tone remains unknown. New treatments reducing neuroinflammation and
GABAergic tone could improve neurological impairment. The aims were, in hyperammonemic rats, to assess
whether:
(a) Enhancing endogenous anti-inflammatory mechanisms by sulforaphane treatment reduces neuroinflammation
and restores learning and motor coordination.
(b)Reduction of neuroinflammation by sulforaphane normalizes extracellular GABA and glutamate-NO-cGMP
pathway and identify underlying mechanisms.
(c) Identify steps by which hyperammonemia-induced microglial activation impairs cognitive and motor function
and how sulforaphane restores them.
Methods: We analyzed in control and hyperammonemic rats, treated or not with sulforaphane, (a) learning in the Y
maze; (b) motor coordination in the beam walking; (c) glutamate-NO-cGMP pathway and extracellular GABA by
microdialysis; (d) microglial activation, by analyzing by immunohistochemistry or Western blot markers of pro-
inflammatory (M1) (IL-1b, Iba-1) and anti-inflammatory (M2) microglia (Iba1, IL-4, IL-10, Arg1, YM-1); and (e)
membrane expression of the GABA transporter GAT-3.
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Results: Hyperammonemia induces activation of astrocytes and microglia in the cerebellum as assessed by
immunohistochemistry. Hyperammonemia-induced neuroinflammation is associated with increased membrane
expression of the GABA transporter GAT-3, mainly in activated astrocytes. This is also associated with increased
extracellular GABA in the cerebellum and with motor in-coordination and impaired learning ability in the Y maze.
Sulforaphane promotes polarization of microglia from the M1 to the M2 phenotype, reducing IL-1b and increasing
IL-4, IL-10, Arg1, and YM-1 in the cerebellum. This is associated with astrocytes deactivation and normalization of
GAT-3 membrane expression, extracellular GABA, glutamate-nitric oxide-cGMP pathway, and learning and motor
coordination.
Conclusions: Neuroinflammation increases GABAergic tone in the cerebellum by increasing GAT-3 membrane
expression. This impairs motor coordination and learning in the Y maze. Sulforaphane could be a new therapeutic
approach to improve cognitive and motor function in hyperammonemia, hepatic encephalopathy, and other
pathologies associated with neuroinflammation by promoting microglia differentiation from M1 to M2.
Keywords: Hyperammonemia, Hepatic encephalopathy, Neuroinflammation, Microglia, Sulforaphane, GAT-3, GABA,
Motor in-coordination, Learning
Background
Hepatic encephalopathy (HE), both clinical and minimal
(MHE), is an important problem which affects several mil-
lion patients with liver cirrhosis worldwide [1]. Patients
with MHE show psychomotor slowing, attention deficits,
mild cognitive impairment, and impaired visuo-motor co-
ordination which reduce the quality of life and the ability
to perform daily life tasks [2, 3].
MHE and HE also pose a relevant economic burden by
increasing the risk of traffic-, work-, and home accidents,
and the number of falls and hospitalizations. Early treat-
ment of patients with HE would improve their quality of
life and life span and reduce accidents, hospitalizations,
and associated costs.
Current treatments for HE are mainly directed to re-
duce ammonia levels by using non-absorbable disaccha-
rides or antibiotics such as rifaximin, which also reduces
inflammation. These treatments are not completely effect-
ive likely because they do not eliminate hyperammonemia
or inflammation which is continuously generated by the
liver disease. Therefore, it is necessary to look for new
treatments acting on a different target involved in the
mechanisms by which liver failure leads to MHE [4].
Hyperammonemia and inflammation play a synergis-
tic role in the induction of the cognitive and functional
alterations in patients with liver cirrhosis and MHE [5–7].
Chronic moderate hyperammonemia, similar to that
present in cirrhotic patients, is enough to induce neu-
roinflammation and neurological alterations in rats
without liver failure [4, 8]. Although liver failure is the
main cause of hyperammonemia, it also occurs in many
other pathological situations, including congenital de-
fects in enzymes of the urea cycle [9], in children with
perinatal asphyxia or preterm delivery [10, 11], Reye’s syn-
drome [12], hyperinsulinism-hyperammonemia syndrome
[13], organic acidemias, and carnitine deficiencies [14].
Hyperammonemia may also arise as complications of
valproate therapy, hemodialysis, or leukemia treatment
[15, 16]. These situations are associated with hyper-
ammonemic encephalopathy [17].
Chronic hyperammonemia induces neuroinflammation
through activation of microglia [8, 18].
The microglial activation marker Iba-1 is also up-
regulated in the cerebral cortex from acutely ammonia-
intoxicated rats [19]. This indicates that hyperammone-
mia per se is enough to induce microglial activation
and neuroinflammation.
Neuroinflammation mediates the cognitive and motor
alterations found in rats with hyperammonemia and HE
and also in patients with different neurological or neuro-
degenerative diseases. Treatment of hyperammonemic
rats or of rats with HE due to portacaval shunts with
anti-inflammatories such as ibuprofen or MAP kinase
p38 inhibitors reduces neuroinflammation and restores
cognitive and motor function [8–18, 20, 21]. This sug-
gests that similar treatments would be useful in patients
with HE. However, both ibuprofen (and other nonsteroi-
dal anti-inflammatory agents, NSAIDs) and inhibitors of
MAP kinase p38 have secondary effects which precludes
its therapeutic use to treat the cognitive and motor alter-
ations in HE. NSAIDs should be avoided in cirrhotic
patients because of risk of renal impairment, hepatorenal
syndrome, and gastrointestinal hemorrhage [22]. Con-
cerning p38 inhibitors, several different molecules have
been evaluated in phase 2 trials. Unfortunately, clinical
efficacy was not observed, and dose-related toxicity was
seen [23].
Chronic hyperammonemia induces neuroinflammation
through activation of microglia [8, 20]. In this work, we
hypothesized that enhancing the endogenous mechanisms
aiming to reduce microglial activation would be useful to
reduce neuroinflammation and restore neurotransmission
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and cognitive and motor function in hyperammonemia
and HE. A good target to reach this aim seems to be
the Nrf2 system, which has been proposed as a thera-
peutic target against brain inflammation [24]. The ac-
tivity of the endogenous Nrf2 system may be enhanced
by some small molecules such as sulforaphane (SFN), a
natural compound derived from cruciferous vegetables
such as broccoli, which dissociates Nrf2 from keap-1,
promoting its translocation to the nucleus and enhance-
ment of antioxidant and anti-inflammatory responses
[24–26]. Sulforaphane reduces lesion progression, infarct
volume, and neurological dysfunction in rodents with
ischemic stroke [27, 28] and is also neuroprotective in
experimental parkinsonism [29].
In this work, we have used a model of chronic hyperam-
monemia without liver failure. It has been shown that most
effects induced by chronic hyperammonemia (including
neuroinflammation) are also present in rats with liver fail-
ure (e.g., [8]). This model has been recommended by the
International Society for Hepatic Encephalopathy to assess
the contribution of hyperammonemia to HE [30].
The first aim of this study was therefore to assess
whether enhancing endogenous anti-inflammatory mech-
anisms by chronic treatment of hyperammonemic rats
with SFN reduces activation of microglia and neuroin-
flammation and restores learning ability.
Neuroinflammation impairs cognitive and motor function
by altering neurotransmission. In HE, hyperammonemia-
induced alterations in GABAergic neurotransmission
contribute to the neurological alterations [4, 31–33].
Chronic hyperammonemia increases extracellular GABA in
cerebellum leading to reduced function of the glutamate-
nitric oxide (NO)-cGMP pathway which, in turn, impairs
the ability to learn a Y maze. Blocking GABAA receptors
with bicuculline reduces GABAergic tone and restores the
function of the pathway and the ability to learn the Y maze
task [32].
As the anti-inflammatory treatments with ibuprofen
or inhibitors of p38 mentioned above also restore the
function of the pathway and learning ability [9, 20], this
suggests that neuroinflammation may be enhancing
extracellular GABA in cerebellum which would mediate
the impairing effects of neuroinflammation on the
glutamate-NO-cGMP pathway and learning. A second
aim of this study was to assess whether reduction of
neuroinflammation in hyperammonemic rats by SFN
normalizes in cerebellum in vivo the glutamate-NO-
cGMP pathway and extracellular GABA concentration
and analyze possible underlying mechanisms.
Increased GABAergic tone also induces motor in-
coordination and extracellular GABA in cerebellum
correlates with motor in-coordination in rats [34].
Gonzalez-Usano et al. [33] showed that treatment with
pregnenolone sulfate reduces extracellular GABA and
restores motor coordination in hyperammonemic rats.
Taking into account these reports, a third aim of this
study was to assess whether treatment with SFN also
restores motor coordination in hyperammonemic rats.
The last aim of this work was to propose a possible se-
quence of the main steps involved in the process by which
hyperammonemia-induced microglial activation leads to
cognitive impairment and motor in-coordination and how
SFN restores them.
To reach the above aims, we analyzed in control and
hyperammonemic rats, treated or not with SFN, (a) the
ability to learn a conditional discrimination task in the Y
maze; (b) motor coordination in the beam walking; (c)
the function of the glutamate-NO-cGMP pathway and
extracellular GABA by in vivo microdialysis in freely
moving rats; (d) microglial activation, by analyzing by
immunohistochemistry or Western blot different pro-
and anti-inflammatory markers (IL-1b, Iba1, IL-4, IL-10,
Arg1, YM-1); and (e) we also assessed whether increased
extracellular GABA is associated with enhanced expres-
sion in membrane of the GABA transporter GAT-3.
Methods
Model of chronic hyperammonemia in rats
Male Wistar rats (120–140 g, Charles River, France) were
made hyperammonemic by feeding them an ammonium-
containing diet as in [35]. The experiments were approved
by the Center and carried out in accordance with the
European Communities Council Directive (86/609/EEC).
Treatment with sulforaphane
Rats were treated daily with sulforaphane (1-Isothiocyanate-
4-methylsulfinylbutane; LKT Laboratory, St. Paul, MN,
USA) or saline. Sulforaphane (SFN) in sterile saline was
injected intraperitoneally at 0.5 mg/kg per day. The dose
was chosen based on previous studies in the literature
[36]. Treatment started 2 weeks after the ammonium-
containing diet and was maintained during all experi-
ments. Injections were performed in sterile conditions
by expert individuals. In spite of long-term i.p. injec-
tions, no complications such as infections, pain, or
needle-induced were observed. Sulforaphane did not
affect body weight or food consumption in control or
hyperammonemic rats [37].
The experimental design is summarized in Fig. 1. The
beam walking test was performed during 3 days begin-
ning on day 22 of hyperammonemia. The microdialysis
experiments were performed during seven working days
beginning on day 35 of hyperammonemia. The sacrifice
was performed during 4 days, beginning on day 49 of
hyperammonemia. These manipulations were not per-
formed exactly on the same day in all rats because it is
technically impossible. In all cases, the manipulations
were performed each day in the same number of rats
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from each group (control; control + sulforaphane, hyper-
ammonemia, and hyperammonemia + sulforaphane). Al-
though the severity of encephalopathy or the effects on
microdialysis parameters may change with time, these
changes occur slowly and remain similar for more than
2 weeks. The results obtained in the different individuals
are therefore comparable.
Learning of a conditional discrimination task in a Y maze
Learning ability was tested as in Aguilar et al. [38] in a
wooden Y-shaped maze. Rats must learn where the food
is depending on the color of the walls. Rats performed
10 trials per day, until the completion of a criterion of
10 correct responses in the same day or a maximum of
250 trials.
Motor coordination: beam walking test
Motor coordination was tested using a wood strip
(20 mm diameter) as described by Gonzalez-Usano et al.
[33]. Rats are made to go through a 1-m-length wooden
stick located approximately 1 m above the ground, and
two observers count the number of slips committed by
the rats. The number of foot faults (slips) is recorded as
a measure of in-coordination.
In vivo microdialysis
Rats were anesthetized using isoflurane, and a microdialy-
sis guide was implanted in the cerebellum (AP −10.2, ML
−1.6, and DV −1.2), as in [29]. After 48 h, a microdialysis
probe was implanted in the freely moving rat. Probes were
perfused (3 μl/min) with artificial cerebrospinal fluid: (in
mM): NaCl, 145; KCl, 3.0; CaCl2, 2.26; buffered at pH 7.4
with 2 mM phosphate. After a 2–3 h stabilization period,
samples were collected every 30 min. When indicated,
NMDA (0.5 mM) was administered to activate the
glutamate-NO-cGMP pathway [39]. Samples were made
4 mM in EDTA and stored at −80 °C until analysis of
cGMP or GABA content.
cGMP determination
cGMP was measured with an enzyme immunoassay kit
from Amersham (Amersham Biotrak GE Healthcare)
using 50 μl of dialysate from cerebellar microdialysis
experiments.
GABA determination
To assess the basal level of extracellular GABA in the
cerebellum, five microdialysis samples were collected be-
fore addition of NMDA. GABA concentration was mea-
sured by HPLC as described by Canales et al. [40].
Membrane surface expression of the GAT-3 trans-
porter by cross-linking with BS3 in cerebellar slices was
analyzed as described by Boudreau and Wolf [41]. Con-
trol and hyperammonemic rats were decapitated and
their brains transferred into ice-cold Krebs buffer (in
mmol/L): NaCl 119, KCl 2.5, KH2PO4 1, NaHCO3 26.2,
CaCl2 2.5, and glucose 11, aerated with 95 % O2 and 5 %
CO2 at pH 7.4. The cerebellum was dissected and trans-
versal slices (400 μm) were obtained using a vibrotome.
Slices were added to tubes containing ice-cold standard
buffer with or without 2 mM BS3 (Pierce, Rockford, IL)
and incubated for 30 min at 4 °C. Cross-linking was ter-
minated by adding 100 mM glycine (10 min, 4 °C). The
slices were homogenized by sonication for 20 s. Samples
treated or not with BS3 were analyzed by Western blot
using anti-GAT-3 (1:2000; Abcam, Cambridge, UK). The
surface expression of GAT-3 was calculated as the differ-
ence between the intensity of the bands without BS3
(total protein) and with BS3 (non-membrane protein).
Analysis of protein content in the cerebellum by Western
blot
The animals were sacrificed by decapitation and the cere-
bellums were dissected and homogenized in 66 mM Tris–
HCl (pH 7.4), 1 % SDS, 1 mM EGTA, 10 % glycerol,
1 mM sodium ortho-vanadate, and 1 mM sodium fluoride
containing protease inhibitor cocktail (Roche, Mannheim,
Germany). Samples were subjected to electrophoresis and
immunoblotting as in Felipo et al. [42]. Primary antibodies
were against IL-4, IL-10, iba-1, Ym-1, and GAT 3 (1:2000)
from Abcam (Cambridge, UK); IL-1β (1:500) from R&D
SYSTEMS (Minneapolis, USA); Arg-1 from BD Bioscience
(NJ, USA); and glial fibrillary acidic protein (GFAP)
(1:5000) from Sigma (St. Louis, MO, USA). As a control
for protein loading, the same membranes were also incu-
bated with anti-actin (Abcam, Cambridge, MA; 1:1000).
Secondary antibodies were anti-rabbit, anti-goat, or
anti-mouse IgG (1:2000) conjugated with alkaline phos-
phatase (Sigma, St. Louis, MO). The images were cap-
tured using the ScanJet 5300C (Hewlett- Packard,
Amsterdam, the Netherlands) and band intensities quanti-
fied using the Alpha Imager 2200, version 3.1.2 (AlphaIn-
notech Corporation, San Francisco).
Immunohistochemistry
Coronal 30-μm sections were cut on a cryostat and stored
at 4 °C in PB with 0.1 % azide until further processing.
Free-floating sections were washed, endogenous peroxidase
activity was quenched with 3 % H2O2 for 15 min, and
Fig. 1 Scheme showing the experimental design
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sequential incubations with blocking serum (normal goat
serum or horse serum) and primary antibodies (overnight
4 °C) were performed. For double immunofluorescence,
corresponding antibodies were incubated together. Primary
antibodies were against IL-4, IL-10, iba-1, and GAT 3 from
Abcam (Cambridge, UK); IL-1β from R&D SYSTEMS
(Minneapolis, USA); and glial fibrillary acidic protein
(GFAP) (1:5000) from Sigma (St. Louis, MO). Incubation
with biotinylated secondary antibodies and with avidin-
biotin-HRP complex (ABC kit, Vector, CA, USA) followed.
The stained sections were mounted on slides, dehydrated,
and coverslipped. For immunofluorescence, secondary anti-
bodies (Alexa fluor, 647 or 488; Invitrogen) were used, and
DAPI was used to visualize cell nuclei.
Statistical analysis
Results are expressed as mean ± SEM. In Figs. 2a, b, 3a,
4a, and 5a–f, data were analyzed by analysis of variance
(one-way ANOVA) with Newman-Keuls multiple post
hoc test. Two-way ANOVA was used in Fig. 3b, with
fraction number and experimental group as variables.
Significance levels were set at p < 0.05.
Results
Blood ammonia levels were 18 ± 3 μM in control rats and
were significantly (p < 0.001) increased in hyperammone-
mic rats to 54 ± 7 μM. Sulforaphane did not affect ammo-
nia levels in control (18 ± 3 μM) or hyperammonemic (49
± 6 μM) rats. These data show that the effects of sulforaph-
ane are not due to reduction of hyperammonemia. The
threefold increase in blood ammonia in hyperammonemic
rats is similar to that reported in cirrhotic patients with
minimal hepatic encephalopathy (2.64-fold) [33].
Sulforaphane improves learning in the Y maze and motor
in-coordination in hyperammonemic rats
Hyperammonemic rats show reduced ability to learn the
Y maze task. They needed more trials (85 ± 7, p < 0.01)
than control rats (65 ± 4) to learn the task. Treatment
with SFN completely restored learning ability in hyper-
ammonemic rats, which needed 64 ± 6 trials to learn the
task. SFN did not affect learning ability in control rats,
which needed 57 ± 4 trials to learn (Fig. 2a).
Motor coordination was analyzed with the beam walk-
ing. Hyperammonemic rats had more foot slips (1.16 ±
0.22, p < 0.01) than control rats (0.65 ± 0.17), indicating
that they have motor in-coordination. Treatment with
SFN restores motor coordination in hyperammonemic
rats, reducing the number of foot slips to 0.32 ± 0.11.
SFN did not affect motor coordination in control rats,
which showed 0.54 ± 0.16 foot slips (Fig. 2b).
Sulforaphane reduces extracellular GABA and restores the
glutamate-NO-cGMP pathway in the cerebellum of hyper-
ammonemic rats
We assessed the effects of treatment with SFN on
extracellular GABA and on the function of the
glutamate-NO-cGMP pathway by microdialysis in vivo
in freely moving rats. As shown in Fig. 3a, extracellular
GABA was increased in hyperammonemic rats (22 ± 2
nM; p < 0.01) compared to control rats (14 ± 2 nM).
Treatment with SFN reduced extracellular GABA in
hyperammonemic rats to 8.5 ± 1.9 nM (p < 0.01) and in
control rats to 11 ± 2 nM.
Figure 3b shows the function of the glutamate-NO-
cGMP pathway. The addition of NMDA through the
microdialysis probe in fraction 6 activates the pathway in
control rats increasing extracellular cGMP to 264 ± 51
and 231 ± 43 % of basal in fractions 7 and 8, respectively.
The NMDA-induced increase in cGMP was strongly re-
duced (p < 0.05) in hyperammonemic rats to 129 ± 25 and
114 ± 15 % of basal in fractions 7 and 8, respectively, indi-
cating reduced function of the glutamate-NO-cGMP
pathway. SFN restores the pathway in hyperammonemic
rats, and NMDA-induced increase of cGMP reached 300
± 49 and 217 ± 31 % of basal, which was not different from
Fig. 2 Treatment with sulforaphane restores learning ability in the Y maze and motor coordination in hyperammonemic rats. Control (C) and
hyperammonemic (HA) rats treated with vehicle (V) or sulforaphane (SFN) were subjected to the conditional discrimination learning test in the Y
maze (a) and the beam walking (b) tests. Values are the mean ± SEM of 11 rats per group in (a) and 22 rats per group in (b). Values significantly
different from control rats are indicated by asterisks. Values significantly different from hyperammonemic rats are indicated by “a”. *p < 0.05; **p < 0.01;
“a” p < 005; “aa” p < 0.01
Hernandez-Rabaza et al. Journal of Neuroinflammation  (2016) 13:83 Page 5 of 13
control rats (Fig. 3b). SFN did not affect the pathway in
control rats.
Sulforaphane normalizes membrane expression of the
GABA transporter GAT-3 and neuroinflammation in the
cerebellum of hyperammonemic rats
A main modulator of extracellular GABA levels is the
transporter GAT-3. As shown in Fig. 4a, the amount of
GAT-3 in the membrane surface is strongly increased
(p < 0.05) in hyperammonemic rats to 251 ± 58 % of
control rats. Treatment with SFN normalized the surface
expression of GAT-3 in hyperammonemic rats, reducing
it to 82 ± 15 % of controls. SFN did not affect GAT-3
expression in control rats, which remained at 115 ± 24 %
of controls (Fig. 4a).
Immunohistochemistry analysis showed that GAT-3 is
expressed mainly in astrocytes surrounding Purkinje cells
(Fig. 4b), and the increase in GAT-3 expression in hyper-
ammonemia occurs mainly in activated astrocytes (Fig. 6k).
No co-localization of GAT-3 and the neuronal marker
Neun was observed when analyzed by double immuno-
fluorescence labeling (Fig. 4c). This is in agreement with
Fig. 3 Sulforaphane normalizes extracellular GABA and the function of the glutamate-NO-cGMP pathway in the cerebellum of hyperammonemic
rats. Control (C) and hyperammonemic (HA) rats treated with vehicle (V) or (SFN) were subjected to in vivo microdialysis in the cerebellum. a
Extracellular GABA was measured by HPLC in the five initial samples of each rat. b After taking five samples to determine basal levels of cGMP,
NMDA 0.5 mM was administered in the perfusion stream, and cGMP was determined in the following five samples to determine to function of
the glutamate-nitric oxide-cGMP. Values are the mean ± SEM of six to eight rats per group. Values significantly different from control rats are
indicated by asterisks. Values significantly different from hyperammonemic rats are indicated by “a”. **p < 0.01; “a” p < 0.05; “aaa” p < 0.001
Fig. 4 Hyperammonemia increases and treatment with sulforaphane normalizes membrane expression of GAT-3 in the cerebellum. a Membrane
expression of GAT-3 was analyzed by Western blot after cross-linking with BS3. A typical image of the blots with and without BS3 is shown.
Membrane expression was quantified as described in methods. Values are the mean ± SEM of six rats per group. Values significantly different
from control rats are indicated by asterisks. Values significantly different from hyperammonemic rats are indicated by “a”. **p < 0.01; “aa” p < 0.01.
b Double immunofluorescence staining of GFAP (green) and GAT-3 (red). Nuclei are stained with DAPI (blue). In the merged image, co-localization
of GAT-3 and GFAP appears in yellow. It can be seen that GAT-3 is expressed in astrocytes surrounding Purkinje neurons (P). c Double
immunofluorescence staining of Neun (red) and GAT-3 (green). Nuclei are stained with DAPI (blue). In the merged image, no co-
localization of GAT-3 and Neun is observed
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the literature showing that GAT-3 is expressed in astro-
cytes [34, 35].
We then assessed whether treatment with SFN reduces
neuroinflammation and microglial activation in hyperam-
monemic rats. The marker of microglial activation Iba-1
was increased (p < 0.05) in hyperammonemic rats to
149 ± 15 % of controls. Treatment with SFN did not
affect Iba-1 content in control or hyperammonemic
rats (Fig. 5a).
The pro-inflammatory cytokine IL-1β is increased in
the cerebellum of hyperammonemic rats to 173 ± 28 %
(p < 0.05) of the control rats. Treatment with SFN nor-
malizes IL-1β in hyperammonemic rats to 123 ± 14 % of
controls and did not affect IL-1β in control rats,
remaining at 116 ± 12 % of control (Fig. 5b).
A main effect of SFN in hyperammonemic rats was
the induction of anti-inflammatory cytokines IL-10 and
IL-4. IL-10 levels were not significantly altered in the
cerebellum of hyperammonemic rats (88 ± 9 % of con-
trols). However, treatment with SFN increased (p < 0.05)
IL-10 in hyperammonemic rats to 159 ± 29 % of control
rats (Fig. 5c). SFN also tended to increase IL-10 in con-
trol rats (137 ± 16 % of controls), but the effect was not
statistically significant.
A similar effect was observed for IL-4. IL-4 levels were
not significantly altered in the cerebellum of hyperam-
monemic rats (104 ± 4 % of controls). Treatment with
SFN strongly increased (p < 0.01) IL-4 in hyperammone-
mic rats to 171 ± 26 % of control rats (Fig. 5d). SFN did
not affect IL-4 in control rats (112 ± 12 % of controls).
These data show that SFN reduces pro-inflammatory
and increases anti-inflammatory cytokines. To assess
whether this could be due to promotion of M2 microglia
polarization, we measured the amount of two main
markers of M2 microglia: arginase 1 and YM-1. Their
amount in the cerebellum was not altered in hyperam-
monemic rats or in control rats treated with SFN.
However, in hyperammonemic rats, treatment with SFN
induces a significant (p < 0.05) increase of arginase 1
(125 ± 14 % of controls, Fig. 5f ) and especially of YM-1,
which increased to 168 ± 21 % of controls (Fig. 5e), indi-
cating M2 polarization of microglia.
The total amount of GFAP, as analyzed by Western
blot, was not affected by hyperammonemia or SFN treat-
ment. However, astrocytes in hyperammonemic rats
show altered morphology (Fig. 6c) compared to controls
(Fig. 6a) when stained with GFAP, indicating astrogliosis,
an activation of astrocytes which is not reflected in the
Fig. 5 Hyperammonemia increases markers of M1 (pro-inflammatory) form of microglia and treatment with sulforaphane increases markers of M2
(anti-inflammatory) form of microglia in hyperammonemic rats. Cerebellar homogenates from control (C) and hyperammonemic (HA) rats treated
with vehicle (V) or sulforaphane (SFN) were subjected to electrophoresis and Western blot using antibodies against a Iba1, marker of microglial
activation; b the pro-inflammatory cytokine IL-1b, marker of M1 microglia; and against the markers of M2 microglia IL-10 (c), IL-4 (d), YM-1 (e),
and Arginase 1 (f). Representative images of the blots are shown for each protein. Values are the mean ± SEM of six to nine rats per group.
Values significantly different from control rats are indicated by asterisks. Values significantly different from hyperammonemic rats are indicated
by “a”. *p < 0.05; **p < 0.01; “a” p < 0.05; “aa” p < 0.01
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total amount of GFAP analyzed by Western blot. In
hyperammonemic rats treated with SFN, the morph-
ology of astrocytes is similar to controls, indicating that
SFN reduces activation of astrocytes.
To assess in which cell types are IL-1b, IL-4, and IL-
10 expressed, we performed co-localization studies by
immunohistochemistry using antibodies against these
ILs and against markers of astrocytes (GFAP) or micro-
glia (Iba-1 and CD11B). The results are shown in Fig. 7.
IL-4 co-localizes both with Iba-1 (Fig. 7a–c) and with
GFAP (Fig. 7d–f ) indicating that it is expressed both in
astrocytes and in microglia. The same occurs with IL-
10 and IL-1b, which co-localize both with microglia
(Fig. 7g–i and m–o, respectively) and astrocytes
(Fig. 7j–l and p–r, respectively). As shown in Fig. 6g, in
hyperammonemic rats, IL-1b is increased in activated
astrocytes and treatment with SFN reduces it.
Discussion
The two main contributions of this article are that it
shows, for the first time, (a) a definite link between neu-
roinflammation, altered GABAergic neurotransmission,
and neurological alterations and (b) the beneficial effects
of sulforaphane to improve hyperammonemic encephal-
opathy. These contributions are discussed in detail below.
Mechanisms by which hyperammonemia-induced neuro-
inflammation leads to cognitive and motor impairment
The results reported provide relevant new data on the
mechanisms by which hyperammonemia-induced neu-
roinflammation leads to cognitive impairment and
motor in-coordination and on how treatment with SFN
reverse them. These data allow proposing the sequence
of events shown in Fig. 8, which can be summarized as
follows. Hyperammonemia induces activation of micro-
glia and of astrocytes which results in increased levels
of Iba1, a marker of microglial activation, and of the
pro-inflammatory IL-1b. This neuroinflammation leads
to enhanced membrane expression of GAT-3, resulting
in enhanced release of GABA and increased extracellu-
lar GABA concentration in the cerebellum. The in-
crease in GABA leads to motor in-coordination and to
reduced function of the glutamate-NO-cGMP pathway
which, in turn, impairs the ability to learn the Y maze
Fig. 6 Hyperammonemia induces and treatment with sulforaphane reduces activation of astrocytes, which express IL-1b and GAT-3.
Immunohistochemistry was performed as indicated in methods with DAB staining using antibodies against GFAP (a–d), IL-1b (e–h), or GAT-3
(i–l). Hyperammonemic rats show an altered morphology of astrocytes stained with GFAP (indicated by arrows), indicating activation (c).
Treatment with SFN reduces astrocyte activation and normalizes the morphology (d). Activated astrocytes in hyperammonemic rats show
increased labeling of IL-1b (g) and GAT-3 (k), which are normalized by treatment with SFN (h, l). m–p Double immunofluorescence staining
of GFAP (red) and Iba-1 (green). Nuclei are stained with DAPI (blue). In the merged image, no co-localization of GFAP and Iba-1 is observed
Hernandez-Rabaza et al. Journal of Neuroinflammation  (2016) 13:83 Page 8 of 13
Fig. 7 IL-4, IL-10, and IL-1b are present both in microglia and astrocytes. The images show immunostaining by double fluorescence of astrocytes (GFAP)
or microglia (Iba-1 or CD11b) and IL-4 (a–f); IL-10 (g–l), or IL-1b (m–r). Arrows indicate co-localization of the labeling of the IL with the corresponding cell
type marker
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task. Impairment of the glutamate-NO-cGMP pathway
and reduction of extracellular cGMP by activation of
GABAA receptors in the cerebellum have been already
reported by Fedele et al. [43] and Cauli et al. [32].
A main contribution of this part of the study is that it
provides a mechanistic link between neuroinflammation
and enhanced GABAergic tone in hyperammonemia: the
increased membrane expression of GAT-3.
Recent studies have clearly shown that hyperammone-
mia induces neuroinflammation, with microglial activa-
tion, that contributes to cognitive and motor alterations
in rat models of hyperammonemia that can be reversed
with anti-inflammatories [8]. Microglial activation has
also been shown in rat models of HE including portaca-
val shunt or bile duct ligation (BDL) [19, 20, 44, 45].
Wright et al. [46] reported that bile duct ligation triggers
early alternative, but not classical, microglial activation.
However, several other groups report classical microglial
activation in BDL rats [8, 44, 45]. Microglial activation is
therefore a general effect in rat models of chronic hyper-
ammonemia and HE.
On the other hand, hyperammonemia also leads to
increased levels of extracellular GABA and enhanced
GABAergic tone in the cerebellum which impairs the
function of the glutamate-NO-cGMP pathway, resulting
in reduced ability to learn the Y maze task [32]. In-
creased extracellular GABA in the cerebellum also con-
tributes to motor in-coordination. Reducing extracellular
GABA and GABAergic tone by modulating GABAA re-
ceptors with the antagonist bicuculline or with the neu-
rosteroid pregnenolone sulfate restores learning ability
and motor coordination [32, 33].
However, it was not known how these two processes
induced by hyperammonemia (neuroinflammation and
enhanced GABAergic tone) are connected. We show here
that neuroinflammation leads to enhanced membrane ex-
pression of GAT-3, mainly in activated astrocytes surround-
ing Purkinje cells, which would be responsible for the
increased levels of extracellular GABA and of enhanced
GABAergic tone which leads both to impaired learning in
the Y maze and to motor in-coordination in the beam
walking.
An increase in the total amount of GAT-3 induced by
pro-inflammatory cytokines such as IL-1b has been re-
ported in the parietal cortex, hippocampus, and amyg-
dala of rats injected with kainate [47]. Under normal
conditions, GAT-3 transports GABA from the extracel-
lular space into astrocytes. However, this transport may
be reversed under pathological conditions. Wu et al. [48]
showed that a mouse model of Alzheimer’s disease
(5xFAD) show activated astrocytes in the hippocampus
which release GABA through GAT-3 transporters.
Blocking GAT-3 transporters reduced GABA concentra-
tion and tonic GABA currents while blocking GAT-1
transporters enhanced GABA currents. This supports
that, under these pathological conditions, GAT-3 is re-
leasing while GAT-1 is uptaking GABA [48]. A similar
GAT-3-mediated release of GABA would occur in acti-
vated astrocytes in the cerebellum of hyperammonemic
rats.
These reports, together with the results reported
here, suggest that enhanced GABAergic tone in certain
brain areas may be a general consequence of neuroin-
flammation which would contribute to the neurological
alterations associated to different neurological and neu-
rodegenerative diseases. Moreover, we show that neuro-
inflammation enhances the membrane expression of
GAT-3. This is very relevant because only GAT-3 in the
membrane can release GABA to the extracellular space.
This study provides therefore a mechanistic link
(modulation of membrane expression of GAT-3) be-
tween neuroinflammation and increased GABAergic
tone and neurological alterations in chronic hyperam-
monemia and HE. Further detailed analysis of the
mechanisms by which neuroinflammation enhances
transport of GAT-3 to the membrane could provide
new therapeutic targets for the cognitive and motor al-
terations not only in hyperammonemia and HE but
also in other pathologies associated to neuroinflamma-
tion, including some neurodegenerative diseases.
Fig. 8 Proposed sequences of events by which hyperammonemia-induced neuroinflammation leads to cognitive and motor impairment (in red)
and treatment with sulforaphane restore them (in green). See details in “Discussion” section
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Treatment with sulforaphane restores learning ability and
motor coordination. Underlying mechanisms
Another main contribution of this work is the identifica-
tion of a new therapeutic tool, sulforaphane, to improve
cognitive and motor function in hyperammonemia and
hepatic encephalopathy. Moreover, we also identify mech-
anisms underlying the beneficial effects of sulforaphane.
Figure 8 also summarizes the mechanism and steps by
which treatment with SFN restores the ability to learn the
Y maze task and motor coordination. The main effect of
SFN is to promote differentiation of microglia from the
pro-inflammatory M1 form to the anti-inflammatory M2
form (see below). This effect is not observed in controls.
This may be attributed to the fact that in control rats,
microglia is not activated, remaining in resting state, not
reaching M1 phenotype. It is not possible therefore to
promote its differentiation from M1 to M2.
Differentiation of microglia from the M1 to the M2
form in hyperammonemic rats is associated with a re-
duction of the pro-inflammatory IL-1b and of astrocytes
activation. Increased expression of GFAP is a hallmark
of activated astrocytes [49, 50]. The intensity of GFAP
immunostaining is increased in astrocytes of hyperam-
monemic rats and is normalized by treatment with sul-
foraphane, indicating reversal of astrocytes activation of
hyperammonemic rats by sulforaphane.
As a result of reduced neuroinflammation, pro-
inflammatory cytokines, and astrocytes activation, the
levels of GAT-3 in the membrane return to normal
levels. As a consequence, extracellular GABA levels also
return to normal levels, allowing normalization of the
glutamate-NO-cGMP pathway and restoration of learning
ability. The normalization of extracellular GABA levels
also leads to improvement of motor coordination.
The fact that SFN, by promoting differentiation of
microglia from the pro-inflammatory M1 form to the
anti-inflammatory M2 form, normalizes all the subse-
quent steps of the process summarized in Fig. 8 further
supports the validity of the sequence of events proposed
for hyperammonemia and HE.
It should be noted that in the present work, there is a
gap between behavioral analysis (performed at weeks 4–6
of hyperammonemia), microdialysis studies (performed at
weeks 6–7), and the sacrifice (performed at week 8
(Fig. 1)). The severity of encephalopathy may differ from
the time of behavioral and microdialysis analysis and the
time of sacrifice. However, we believe that this gap is small
and would not affect the main conclusions of the study,
summarized in Fig. 8.
Microglial activation is the principal component of
neuroinflammation in the brain, which execute both det-
rimental and beneficial effects on the neurons in many
pathological situations. Microglia may present diverse
functional phenotypes that range from pro-inflammatory
M1 phenotype, the first line of defense, to immunosup-
pressive M2 phenotype, which includes alternative acti-
vation and acquired deactivation [51]. Markers of M1
phenotype are IL-1b or nitric oxide and markers of M2
are Il-4, IL-10, arginase 1 (Arg 1), and YM-1 [51]. It has
been proposed that manipulation of microglia pheno-
types from pro-inflammatory, cytotoxic M1 to anti-
inflammatory, neuroprotective M2 may be a therapeutic
approach in some neurodegenerative diseases associated
with neuroinflammation such as Alzheimer’s or Parkin-
son’s diseases and amyotrophic lateral sclerosis [51].
The results reported here show that treatment with
sulforaphane successfully promotes this polarization of
microglia to neuroprotective M2 phenotype in cerebel-
lum of hyperammonemic rats, increasing M2 markers
(IL-4, IL-10, Arg 1, and YM-1) and reducing M1
markers (IL-1b).
This is associated with improvement of cognitive func-
tion and motor coordination which would be mediated
by deactivation of astrocytes. In pathological conditions,
there is a cross-talk between activation of microglia and
astrocytes. Microglia is activated earlier than astrocytes
and promotes activation of astrocytes, which is mediated
mainly by IL-1b released from microglia [52]. As men-
tioned above, activated astrocytes show increased
amount and membrane expression of GAT-3, resulting
in increased release and extracellular levels of GABA
which in turn induces motor in-coordination and cogni-
tive impairment.
As summarized in Fig. 8, we show that treatment
with sulforaphane promotes the M2 phenotype, redu-
cing microglial activation and normalizing IL-1b levels.
This is associated with deactivation of astrocytes and
normalization of membrane expression of GAT-3 and
of extracellular GABA levels. This normalizes GABAer-
gic neurotransmission and restores motor coordination
and learning ability.
The above beneficial effects of sulforaphane would be
due to a direct effect on the brain. In the rat model used,
chronic hyperammonemia is obtained by feeding rats an
ammonium-containing diet. In this model, there is no
liver damage [53]. The effects of sulforaphane cannot be
due therefore to improvement of liver failure. Sulforaph-
ane is a natural compound present in cruciferous vegeta-
bles such as broccoli. In addition to pharmacological
treatments with compounds that promote differentiation
of M1 microglia to M2, maybe including these vegeta-
bles in the diet of patients may help to improve their
cognitive and functional status.
Conclusions
In summary, this work shows for the first time that
hyperammonemia-induced activation of microglia, neu-
roinflammation, and increased extracellular GABA are
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associated with increased levels (mainly in activated astro-
cytes) and membrane expression of GAT-3, that releases
GABA from cells to the extracellular fluid. Increased
GABAergic tone has been shown to mediate impairment
of motor coordination and of learning of the Y maze task
in hyperammonemia and HE. Treatment with sulforaph-
ane restores this learning ability and motor coordination
by promoting the differentiation of microglia from the M1
to the M2 phenotype, reducing the levels of IL-1b and de-
activating astrocytes. This is associated with reduced
membrane expression of GAT-3 and extracellular GABA.
The process depicted in Fig. 8 linking neuroinflammation
with enhanced GABAergic tone and impaired learning
ability and motor coordination would occur not only in
hyperammonemia and HE but also in other pathological
situations leading to neuroinflammation, including some
neurodegenerative diseases. Promoting differentiation of
microglia from M1 to M2 phenotypes, with sulforaphane
or other compounds, could be a new therapeutic approach
to improve cognitive and motor function in these situa-
tions, including hyperammonemia and HE.
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